Plain-English translation of NCT06251310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new drug called in people with advanced solid tumors that have stopped responding to standard cancer treatments. The study has two main phases: first, researchers will test different doses of the medication to find the safest and most effective dose, and then they will expand the trial to test that dose in larger groups of patients with specific types of tumors or genetic mutations.
Many advanced cancers stop responding to current treatments, leaving patients with very limited options. This medication is designed to target specific genetic mutations in cancer cells (called Hippo pathway mutations), which appear in certain types of advanced tumors. By testing this new treatment, researchers hope to offer a potential option for people whose cancers are no longer responding to available therapies.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as tablets in 28-day cycles. During the first phase, researchers will gradually increase the dose for different groups of patients to find the right dose; in the second phase, patients receive the dose determined to be safest and most effective. You will have regular visits for blood tests, imaging scans, and physical exams to monitor how you are responding and check for side effects. The trial is open-label, meaning both you and the research team will know you are receiving this medication.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States